Probity Advisors’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.68M Sell
12,021
-419
-3% -$58.7K 0.27% 70
2025
Q4
$1.53M Sell
12,440
-653
-5% -$79.4K 0.24% 75
2025
Q3
$1.45M Sell
13,093
-423
-3% -$48.1K 0.24% 74
2025
Q2
$1.5M Sell
13,516
-390
-3% -$41.5K 0.26% 67
2025
Q1
$1.56M Sell
13,906
-545
-4% -$56.2K 0.3% 63
2024
Q4
$1.33M Sell
14,451
-751
-5% -$67.6K 0.26% 66
2024
Q3
$1.27M Buy
15,202
+1,496
+11% +$114K 0.24% 76
2024
Q2
$940K Buy
13,706
+2,222
+19% +$148K 0.19% 95
2024
Q1
$841K Sell
11,484
-171
-1% -$13.1K 0.17% 104
2023
Q4
$944K Buy
11,655
+1,387
+14% +$108K 0.21% 96
2023
Q3
$769K Buy
10,268
+775
+8% +$59.6K 0.18% 86
2023
Q2
$732K Buy
+9,493
New +$757K 0.16% 93
2022
Q4
$775K Sell
9,026
-222
-2% -$17.6K 0.18% 87
2022
Q3
$571K Sell
9,248
-1,372
-13% -$86.5K 0.14% 96
2022
Q2
$656K Buy
10,620
+183
+2% +$11.3K 0.15% 95
2022
Q1
$620K Sell
10,437
-156
-1% -$9.97K 0.13% 110
2021
Q4
$769K Buy
10,593
+507
+5% +$34.9K 0.15% 108
2021
Q3
$705K Buy
10,086
+696
+7% +$48.9K 0.15% 109
2021
Q2
$647K Buy
9,390
+1,477
+19% +$98.6K 0.14% 117
2021
Q1
$511K Buy
+7,913
New +$510K 0.11% 125
2020
Q3
$309K Buy
4,894
+972
+25% +$67.4K 0.09% 144
2020
Q2
$302K Buy
+3,922
New +$301K 0.09% 147

Other funds holding GILD

Probity Advisors's GILD Position: Q1 2026 in Review

Probity Advisors reduced its Gilead Sciences (GILD) stake by 3.4% in Q1 2026, selling an estimated $58.7K and leaving 12,021 shares worth $1.68M. The position accounts for 0.27% of the portfolio, ranked #70.

Probity Advisors first reported a position in GILD in Q2 2020 and has held it in 22 quarters since. 2,309 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

  • Probity Advisors held 12,021 shares of Gilead Sciences worth $1.68M as of Q1 2026.
  • Probity Advisors sold 419 Gilead Sciences shares in Q1 2026, an estimated $58.7K.
  • Gilead Sciences made up 0.27% of Probity Advisors's portfolio in Q1 2026, its #70 holding.
  • Probity Advisors first reported a position in Gilead Sciences in Q2 2020 and has held it in 22 quarters since.
  • 2,309 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on Probity Advisors's 13F filing for Q1 2026, filed 28 Apr 2026.